X T L Biopharmaceuticals XTLB.TA · ILA

Its shares trade on Tel Aviv under the ticker XTLB.TA. It has been listed since 1 September 2000. In the fiscal year to 31 December 2024, it reported revenue of $451,000 and a net loss of $1.0m. At that date it held total assets of $8.6m and shareholders' equity of $5.4m.

XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company is headquartered in New York City, New York. The company went IPO on 2000-09-01. The firm is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Doron TurgemanNon-Executive Chairman of the Board, since 2014
• Mr. Shlomo ShalevChief Executive Officer, Director, since 2014
• Mr. Itay WeinsteinChief Financial Officer
• Dr. Dobroslav MelamedNon-Executive Director
• Mr. Alexander RabinovitchNon-Executive Director
• Dr. Jonathan SchapiroNon-Executive Director
• Ms. Osnat FainNon-Executive Independent Director
• Ms. Iris YalonNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.